The effectiveness of a training package to teach listening and helping skills to three pairs of sexual harrassment contact person trainees was evaluated, using a multiple probe design. The training package comprised five components: behavioral specifications, rationales, situational examples, study guides, and role-play exercises, provided in a written instructional format based on guidelines developed by Fawcett and Fletcher. Evaluation involved pre- and posttraining measures of target behavior occurrence, relevant knowledge, and self-rated confidence level. Ratings of performance were also provided by potential consumers as a measure of social validity. Findings indicated that the package was effective in increasing listening and helping skills, knowledge, and confidence of trainees and that skills generalized to new simulated cases and were maintained over time.

Background Add‐ons at the time of in vitro fertilisation (IVF) have become commonplace, despite a general lack of evidence that they are effective and safe. The ‘Colorado Protocol’ is a commonly used add‐on consisting of aspirin, steroid and an antibiotic. Before commencing planning for a clinical trial evaluating the Colorado Protocol, researchers and funders need evidence that the Colorado Protocol is being prescribed, and to be assured that sufficient numbers of participants can be recruited for a clinical trial. Aims To survey fertility clinicians and patients on attitudes toward use of add‐ons during IVF, willingness of patients to be randomly assigned to an add‐on trial treatment or placebo, and what would be the clinically meaningful outcomes, using the Colorado Protocol as a test case. Materials and methods Two online surveys were conducted: clinicians from fertility clinics across the United Kingdom, Australia, and New Zealand; and patients from Auckland‐based clinics and NZ patient support groups. Results Of 58 clinicians, 44 (75%) had recommended an add‐on within the preceding year. Thirty‐nine (67%) clinicians were aware of the Colorado Protocol, with 17 (29%) having recommended it within the preceding year. Of the 289 patients, 80% indicated willingness to take trial medications during IVF, and 68% were willing to be randomly assigned to the placebo arm of a trial. The median perceived minimum clinically important difference in live births in both samples was 5%. Conclusions A future trial of this add‐on in IVF would be supported by patients in the context of the New Zealand fertility healthcare system.